Robert Bitman represents public and private companies in a wide range of corporate and securities matters, including entity formation, private financings, public offerings, SEC reporting and compliance, corporate governance and mergers and acquisitions.

Download full bio 


  • Travere Therapeutics – $316 Million Convertible Note Offering 

  • Nuvation Bio to Combine With Panacea, a Special Purpose Acquisition Company 

  • Billtrust to Combine With South Mountain, a Special Purpose Acquisition Company, at $1.3 Billion Value 

  • Inhibrx – $137 Million IPO 

  • Avidity Biosciences - $289 Million IPO 

  • View all


  • University of San Diego School of Law
    JD, cum laude, 2019

  • University of California, Santa Barbara
    BA, Political Science

Admissions & Credentials